01—Abstract
Summary
Summary of the 8-K filed May 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. filed this Current Report on Form 8-K to disclose a leadership transition in its medical function and related compensatory arrangements.
Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts has served as Chief Medical Officer for the past seven years and will remain with the Company in a strategic advisory role following Dr. Keswani's succession.
In connection with the transition, the Company entered into an Amended and Restated Employment Agreement with Dr. Roberts on May 30, 2025, effective upon the later of June 2, 2025 and the date the new Chief Medical Officer commences employment. The agreement amends and restates her employment agreement dated February 7, 2025. Under the amended agreement, Dr. Roberts will serve as Strategic Advisor to the CEO from the transition date through December 31, 2025, with an annual base salary of $731,400a and a target annual cash incentive bonus equal to 60% of base pay earned for calendar year 2025.
The agreement also provides substantially the same severance benefits she was previously eligible for under the Company's Executive Severance Plan adopted February 7, 2025, and her outstanding equity awards will remain outstanding and continue to vest according to their terms. The filing is primarily an executive-transition disclosure and does not indicate any change to the Company's financial results or guidance.
02—Key points
Key Highlights
- Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025.
- Dr. Roberts has served as Chief Medical Officer for the past seven years and will continue as a strategic advisor.
- Amended and Restated Employment Agreement with Dr. Roberts entered into May 30, 2025, effective upon the later of June 2, 2025 and the new CMO's start date.
- Dr. Roberts will serve as Strategic Advisor to the CEO through December 31, 2025.
- Annual base salary of $731,400 and target annual cash incentive bonus of 60% of base pay for calendar year 2025.
- Severance benefits substantially the same as under the Executive Severance Plan adopted February 7, 2025; outstanding equity awards continue to vest per their terms.
- Full agreement filed as Exhibit 10.1 (Amended and Restated Employment Agreement dated May 30, 2025).
03—Questions
Frequently Asked Questions
Who is replacing Eiry W. Roberts, M.D. as Chief Medical Officer?
Sanjay Keswani, M.D. will succeed Dr. Roberts as Chief Medical Officer of the Company, effective June 2, 2025.
What role will Dr. Roberts have after the transition?
Dr. Roberts will serve as Strategic Advisor to the CEO from the Transition Date through December 31, 2025, and will remain with the Company in that advisory role.
What compensation will Dr. Roberts receive under the amended agreement?
She will continue to receive an annual base salary of $731,400 and is eligible for an annual cash incentive bonus with a target equal to 60% of her base pay earned for calendar year 2025.
What happens to Dr. Roberts' equity awards and severance benefits?
Her outstanding equity awards will remain outstanding during her employment and continue to vest in accordance with their terms. The agreement provides substantially the same severance benefits she was previously eligible for under the Executive Severance Plan adopted February 7, 2025.
When does the amended employment agreement take effect?
The agreement was entered into on May 30, 2025, and becomes effective upon the later of June 2, 2025 and the date the new Chief Medical Officer begins employment.
04—Continue